Yair Lotan, MD
Urology · Dallas, TXNPI 1407815541
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $327,983 of the $371,309 with a category attached, or 88.3%. 53 manufacturers reported payments, led by Photocure Inc at 25.7% of the total. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $1298.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Photocure Inc$96K
- Urogen Pharma, Inc.$86K
- Merck$44K
- Ambu Inc.$34K
- Pfizer$21K
- Ferring Pharmaceuticals Ltd.$17K
- plus $74K from 47 others
Across 101 payments — averaging $6929.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$381K
- Photocure Inc$97K
- Pfizer$86K
- Seagen Inc.$66K
- KARL Storz Endoscopy-america$57K
- Urogen Pharma, Inc.$6K
- plus $6K from 4 others
What the payments were for
- Consulting fees$327,98388%
- Speaking & faculty fees$22,5756%
- Travel & lodging$11,7153%
- Food & beverage$9,0212%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$371,309 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 80 | $74,761 |
| Tamsulosin Hcl | 476 | $10,236 |
| Finasteride | 324 | $5,139 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $3,620 |
| Silodosin | 25 | $2,663 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 105 | $1,314 |
| Oxybutynin Chloride ErOxybutynin Chloride | 75 | $1,141 |
| Solifenacin Succinate | 21 | $887 |
| NitrofurantoinNitrofurantoin Macrocrystal | 16 | $784 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $525 |
| Megestrol Acetate | 13 | $373 |
| Dutasteride | 15 | $346 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 64 | $309 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $134 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $90 |
Paid to pharmacies, not to this prescriber.
Other urology in Dallas
- Allen MoreyDallas$914K
- Vitaly MargulisDallas$555K
- Claus RoehrbornDallas$169K
- Samantha NealonDallas$89K
- Maia VandykeDallas$79K
- Gary LemackDallas$62K
- Brian LangfordDallas$57K
- Jonathan SeamanDallas$55K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.